Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 7/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 6/20 | 0.51 |
| ▸ | HTR7 | P34969 | 4/20 | 0.51 |
| ▸ | DRD4 | P21917 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577767 | 0.95 | MAPK1 (0.62) | MAPK1ALDH1A1KDM4EKMT2ADRD2 | |
| SCHEMBL5577694 | 0.84 | SIGMAR1 (0.51) | ALDH1A1KMT2ADRD2DRD3DRD4 | |
| SCHEMBL5577434 | 0.81 | MAPK1 (0.51) | MAPK1KMT2ADRD2DRD3DRD4 | |
| SCHEMBL5577575 | 0.79 | DRD3 (0.53) | MAPK1ALDH1A1KMT2ADRD2DRD3 | |
| SCHEMBL5577433 | 0.78 | DRD2 (0.53) | MAPK1DRD2HTR1ADRD3HTR7 | |
| SCHEMBL5577394 | 0.78 | CNR2 (0.49) | MAPK1DRD2HTR1ADRD3DRD4 | |
| SCHEMBL5577639 | 0.77 | LMNA (0.61) | MAPK1KMT2ADRD2HTR1AHTR7 | |
| SCHEMBL5577456 | 0.77 | KMT2A (0.53) | MAPK1ALDH1A1KMT2ADRD2DRD3 | |
| SCHEMBL5577597 | 0.77 | DRD2 (0.52) | MAPK1ALDH1A1KDM4EKMT2ADRD2 | |
| SCHEMBL5577445 | 0.76 | CHRM3 (0.51) | MAPK1ALDH1A1KDM4EKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | MAPK1 592/4885ALDH1A1 1147/4885KDM4E 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.